The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9441041 B1

PDF
Full Text
Expired
Date of Patent:
Sep. 13, 2016

Filed:

Sep. 21, 2015
Applicant:

The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Washington, DC (US);

Inventors:

James Arthos, Rockville, MD (US);

Diana Goode, Bellingham, MA (US);

Claudia Cicala, Bethesda, MD (US);

Anthony S. Fauci, Washington, DC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 38/12 (2006.01); C07K 16/28 (2006.01); G01N 33/569 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2842 (2013.01); A61K 38/12 (2013.01); C07K 16/2839 (2013.01); G01N 33/56988 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); G01N 2333/7055 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/70553 (2013.01); G01N 2500/02 (2013.01); G01N 2500/10 (2013.01);
Abstract

Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the HIV infection. In several examples, the α4 integrin antagonist is a monoclonal antibody that specifically binds to a α4, β1 or β7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.


Find Patent Forward Citations

Arthos, James. (2016). Use of antagonists of the interaction between hiv gp120 and α4β7 integrin (U.S. Patent No. 9441041). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9441041

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…